| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | blood clotting, blood coagulation | ÇÑ±Û | Ç÷¾×ÀÀ°í |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀÌ»ó ³ªÁö ¾Ê°Ô ÇÏ´Â °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. ù¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô ÇÏ¸é ¿ì¼± Ç÷°üÀÇ ¼Õ»óºÎÀ§·Î ºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »óó¸¦ ¸·°í ÀÖ´Â Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼ ´õ¿í ´Ü´ÜÇÏ°Ô ÇÏ¿© »óó°¡ ³ Ç÷°ü¿¡¼ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇÏ´Â °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©ÇÏ´Â ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇÏ´Â °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾÙ. Ç÷¾×ÀÀ°í¶õ µÎ¹øÂ° ´Ü°è¸¦ ÁöĪÇÏ´Â ¸»·Î½á ¸Å¿ì º¹ÀâÇÑ ´Ü°è¸¦ °ÅÄ¡´Â ¹ÝÀÀÀ¸·Î ¸¶Áö¸· ´Ü°è´Â ¼¶À¯¼Ò¶ó´Â ¹°ÁúÀÌ ¸¸µé¾îÁ®¼ ÀÌ ¹°ÁúÀÌ Ç÷¼ÒÆÇ°ú ±× ¿ÜÀÇ ¼¼Æ÷¸¦ ´Ü´ÜÇÏ°Ô °íÁ¤½ÃÄÑ Çǰ¡ »óó³ Ç÷°üÀ¸·Î »õ´Â °ÍÀ» ¸·´Â´Ù. À̰ÍÀ» °¡Àå °£´ÜÈ÷ ¼³¸íÇÏÀÚ¸é Å©°Ô ´ÙÀ½°ú °°Àº 3°¡Áö ´Ü°è·Î ÀÌ·ç¾îÁø´Ù. ù¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼ ÇÁ·ÎÆ®·Òºó Ȱ¼ºÁ¦¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ ÇÁ·ÎÆ®·Òºó Ȱ¼ºÁ¦¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ Ç÷¾×¼Ó¿¡ ÀÖ´Â ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. |
||
| ¿µ¹® | cardiotonic, cardiotonic agent | ÇÑ±Û | °½ÉÁ¦ |
|---|---|---|---|
| ¼³¸í | ½ÉÀåÀÇ ¼öÃà·ÂÀ» Áõ°¨½ÃŰ´Â ¾à¹°À» ¸»ÇÑ´Ù. ±âº»ÀûÀ¸·Î ½É±Ù¼öÃà·ÂÀ» Áõ°½ÃÄÑ ½ÉÀå¹ÚÃâ·®À» Áõ°¡½ÃŰ´Â ¾à¹°ÀÌ´Ù. °½É¹è´çü, Æ÷½ºÆ÷µð¿¡½ºÆ®¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, ¾Æµå·¹³¯¸° ¥â¼ö¿ëüÀÛ¿ëÁ¦, Ç÷°üÈ®ÀåÁ¦ µîÀÌ ÀÖ´Ù. ´ëÇ¥ÀûÀÎ ¿¹·Î¼´Â µð°î½Å(digoxine) µîÀÇ µðÁöÅ»¸®½º(digitalis)°¡ ÀÖ´Ù. |
||
| ¿µ¹® | alkylating agent | ÇÑ±Û | ¾ËųȾ๰ |
|---|---|---|---|
| ¼³¸í | Ç×¾ÏÁ¦ÀÇ ÀÏÁ¾. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÇØ¸¦ ÁÖÁö ¾Ê°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇØ¾ß ÇÑ´Ù. ÇöÀç ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº ´Ù½Ã ¸»Çϸé À¯Àü Á¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â Á¤»óÀûÀÎ ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î ÀÌµé ¼¼Æ÷µµ ÇÔ²² Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ Àß ¿Â´Ù). ¾ËĮȾ๰ÀÇ °æ¿ì¿¡´Â DNA¿Í Á÷Á¢ °áÇÕÀ» ÇÏ¿© DNAÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÁ¦ÀÇ ¿ªÇÒÀ» ¼öÇàÇÑ´Ù. |
||
| ¿µ¹® | anti-inflammatory agent | ÇÑ±Û | Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à |
|---|---|---|---|
| ¼³¸í | ±¹¼Ò¿¡ ÀÛ¿ëÇÏ¿© ¿°ÁõÀ» Ä¡·áÇÏ°í ¹æÁöÇÏ´Â ¾à. ¿°ÁõÀ» °¡¶ó¾ÉÈ÷´Â ¾àÀ» ¸»ÇÑ´Ù. Á¶Á÷À» ±äÃà-Ä¡¹ÐÇÏ°Ô ÇÏ¿© Àå¾×°ú Á¡¾×ÀÇ ºÐºñ¸¦ ÁÙÀ̰í, Ç¥¸é¿¡ ÀÖ´Â ÀÛÀº Ç÷°ü¿¡ ºóÇ÷À» ÀÏÀ¸ÄÑ ÃæÇ÷µÇ´Â °ÍÀ» ¹æÁöÇÔÀ¸·Î½á ¿°ÁõÀû º´º¯À» Á¦°ÅÇÏ¿© ¸ðµç Áõ¼¼¸¦ ¾ø¾Ø´Ù. ´ëºÎºÐÀÇ ¼ö·ÅÁ¦-¿ÏÈÁ¦-Áø¾çÁ¦°¡ ÀÌ¿¡ ¼ÓÇÑ´Ù. Áß¿äÇÑ ¼ººÐÀ¸·Î´Â ¾Ë·ç¹Ì´½-ºñ½º¹«Æ®-¾Æ¿¬-³³ÈÇÕ¹°(º´¹Ý-Æä¸£¸¶Åç-¾Æ¿¬È-¿¬´ç µî) µîÀÌ ÀÖ´Ù. ÀÛ¿ë¿¡ µû¶ó Ç׿°ÁõÁøÅëÁ¦¿Í Ç׿°ÁõÈ¿¼ÒÁ¦·Î ³ª´¶´Ù. |
||
| ABC | absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a... |
|---|---|
| CBV | capillary blood cell velocity; catheter balloon valvuloplasty; central blood volume; cerebral blood ... |
| STANDOUT | soft thresholding and depth cueing of unspecified techniques |
| URD | unspecified respiratory disease; upper respiratory disease |
| SMCA | smooth muscle contracting agent; suckling mouse cataract agent |
| AOD | and other drug |
|---|---|
| DRO | Differential Reinforcement of Other Behaviour |
| MOTT | Mycobacteria Other Than Tuberculosis |
| OND | Other Neurological Diseases |
| SO | significant other |
acute angle
| other-directed | Pertaining to a person readily influenced by the attitudes of others. (05 Mar 2000) |
|---|---|
| transferases (other substituted phosphate groups) | <enzyme> A class of enzymes that transfers substituted phosphate groups. Registry number: EC 2.7.8 (12 Dec 1998) |
| blood grouping and crossmatching | Testing erythrocytes to determine presence or absence of blood-group antigens, testing of serum to determine the presence or absence of antibodies to these antigens, and selecting biocompatible blood by crossmatching samples from the donor against samples from the recipient. Crossmatching is performed prior to transfusion. (12 Dec 1998) |
| Novy and MacNeal's blood agar | A nutrient agar containing two volumes of defibrinated rabbit's blood; suitable for the cultivation of a number of trypanosomes. (05 Mar 2000) |
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| agent | <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological. Origin: L. Agens = acting (18 Nov 1997) |
| agent, antihypertensive | As the name suggests, a drug aimed at reducing high blood pressure (hypertension). (12 Dec 1998) |
| agent, anti-infective | Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. (12 Dec 1998) |
| Agent Orange | An herbicide and defoliant, consisting of (2,4,5-trichlorophenoxy)acetic acid, (2,4-dichlorophenoxy)acetic acid, and dioxin, that was widely used in the Vietnam War; it has been shown to possess residual post-exposure carcinogenic and teratogenic properties in humans. (05 Mar 2000) |
| agent, tocolytic | A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born. (12 Dec 1998) |
| alkylating agent | <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells. Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan. (29 Sep 1997) |
| alpha-adrenergic blocking agent | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
| antianxiety agent | A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam). Synonym: anxiolytic, minor tranquilliser. (05 Mar 2000) |
| antidiabetic agent | A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin. (09 Oct 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|